News Agency
Men's Weekly

Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors

  • Written by PR Newswire
Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors

TOULOUSE, France, Nov. 9, 2020 /PRNewswire/ -- Pierre Fabre announced today the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, an innovative monoclonal antibody targeting VISTA, developed by Pierre Fabre Medical Care R&D teams. The study...

Read more: Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody...

The Real Value of All-on-4: Brisbane Dentists Explain the Long-Term Benefits

Tooth loss can be a distressing and life-altering experience. Beyond the immediate impact on chewing, speaking, and appearance, missing teeth can lead to declining self-confidence, social anxiety, and long-term oral health complications. Fortunately, modern dental technology has revolutionised tooth replacement... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion